Skip to main content
Clinical Trials/RBR-86kcy37
RBR-86kcy37
Not Yet Recruiting
Phase 3

Evaluation of the efficacy and safety of pediatric praziquantel in children residing in endemic areas of Bahia and Sergipe

Instituto Gonçalo Moniz (IGM) - Fundação Oswaldo Cruz (Fiocruz-BA)0 sitesJune 14, 2024

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Instituto Gonçalo Moniz (IGM) - Fundação Oswaldo Cruz (Fiocruz-BA)
Status
Not Yet Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 14, 2024
End Date
December 31, 2025
Last Updated
last year
Study Type
Intervention

Investigators

Sponsor
Instituto Gonçalo Moniz (IGM) - Fundação Oswaldo Cruz (Fiocruz-BA)

Eligibility Criteria

Inclusion Criteria

  • Age between 4 and 6 years (cohort 1\) and 3 months to 3 years (cohort 2\); presence of at least 1 Schistosoma mansoni egg detected through parasitological methods; minimum body weight of 8 kg for children between 2 and 6 years and 5 kg for children under 2 years

Exclusion Criteria

  • Presence of conditions that contraindicate the use of praziquantel at the discretion of the physician, such as viral or bacterial infections, diarrhea, gastroenteritis, among others; have undergone treatment with praziquantel in the last 6 months; concomitant treatment with other drugs that can affect the metabolism of praziquantel, such as some antiepileptics, glucocorticoids, chloroquine, rifampicin, or cimetidine; participants with hepatosplenic schistosomiasis; participants with body temperature above 37\.5°C

Outcomes

Primary Outcomes

Not specified

Similar Trials